- Home
- CGEM vs PSNL Comparison
CGEM vs PSNL Comparison
Compare CGEM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- PSNL
- Stock Information
- Founded
- CGEM 2016
- PSNL 2011
- Country
- CGEM United States
- PSNL United States
- Employees
- CGEM N/A
- PSNL N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- CGEM Health Care
- PSNL Health Care
- Exchange
- CGEM Nasdaq
- PSNL Nasdaq
- Market Cap
- CGEM 506.1M
- PSNL 460.7M
- IPO Year
- CGEM 2021
- PSNL 2019
- Fundamental
- Price
- CGEM $7.89
- PSNL $3.19
- Analyst Decision
- CGEM Strong Buy
- PSNL Strong Buy
- Analyst Count
- CGEM 7
- PSNL 5
- Target Price
- CGEM $32.86
- PSNL $7.80
- AVG Volume (30 Days)
- CGEM 520.6K
- PSNL 733.3K
- Earning Date
- CGEM 05-14-2025
- PSNL 05-07-2025
- Dividend Yield
- CGEM N/A
- PSNL N/A
- EPS Growth
- CGEM N/A
- PSNL N/A
- EPS
- CGEM N/A
- PSNL N/A
- Revenue
- CGEM N/A
- PSNL $84,614,000.00
- Revenue This Year
- CGEM N/A
- PSNL N/A
- Revenue Next Year
- CGEM N/A
- PSNL $27.78
- P/E Ratio
- CGEM N/A
- PSNL N/A
- Revenue Growth
- CGEM N/A
- PSNL 15.15
- 52 Week Low
- CGEM $6.85
- PSNL $1.14
- 52 Week High
- CGEM $30.19
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- CGEM 47.24
- PSNL 42.50
- Support Level
- CGEM $6.93
- PSNL $2.86
- Resistance Level
- CGEM $8.10
- PSNL $3.40
- Average True Range (ATR)
- CGEM 0.52
- PSNL 0.33
- MACD
- CGEM 0.07
- PSNL 0.04
- Stochastic Oscillator
- CGEM 83.20
- PSNL 40.27
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.